In a clinical trial for patients with hypomethylating agent-refractory AML, its combination with azacitidine proved feasible and yielded a composite response rate of 20%, demonstrating preliminary efficacy of HMGB1 therapeutic targeting in this high-risk population [248]. This evidence concerns the gene HMGB1 and acute myeloid leukemia.